id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0327-0002,FDA,FDA-2003-E-0327,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-24T05:00:00Z,2003,11,,,2025-10-22T16:55:51Z,,0,0,090000648049589b
FDA-2003-E-0327-0001,FDA,FDA-2003-E-0327,Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX,Notice,General Notice,2003-04-22T04:00:00Z,2003,4,2003-04-17T04:00:00Z,,2025-10-22T16:44:18Z,03-9536,0,0,0900006480495890